To be specific, the GEO dataset analyzed by PrognoScan indicates that high expression of ACSL4 is associated with poor prognosis in Colorectal cancer and Brain cancer, and low expression of ACSL4 is associated with poor prognosis in Lung and Breast cancer. Here, ACSL4 is linked to brain cancer.